Gonadorelin
Highest phase reached
Approved
Drug type
Protein
First approval year
1982
- First approval year
- 1982
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Protein
- Drug name
- Gonadorelin
- Molecular weight
- 1,182.31
- Structure (SMILES)
- CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
- fertiral lh rh
- Fertiral lh-rh
- relefact lh rh
- Relefact lh-rh
- 5 oxopro his trp ser tyr gly leu arg pro gly nh2
- 5-OXOPRO-HIS-TRP-SER-TYR-GLY-LEU-ARG-PRO-GLY-NH2
- Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues
- auxiliary medicinal product luteinizing hormone releasing hormone lhrh analogues
- gnrh
- GNRH
- gonadorelin
- Gonadorelin
- GONADORELIN (GONADORELIN DECAPEPTIDE (GNRH))
- gonadorelin [INN]
- GONADORELIN [JAN]
- GONADORELIN [MART.]
- GONADORELIN [MI]
- GONADORELIN [VANDF]
- Gonadorelin [WHO-DD]
- gonadorelin decapeptide
- Gonadorelin decapeptide
- gonadorelin gonadorelin decapeptide gnrh
- gonadorelin inn
- gonadorelin jan
- gonadorelin mart
- gonadorelin mi
- gonadorelin vandf
- gonadorelin who dd
- gonadorelina
And 25 more, listed on the interactive page.
- CAS registry numbers
- 33515-09-2
- ChEMBL ID
- CHEMBL1007
- InChIKey
- XLXSAKCOAKORKW-AQJXLSMYSA-N
- PubChem compound IDs
- 638793
- FDA ingredient codes (UNII)
- 9O7312W37G
- H01CA01
- V04CM01
Sources for recorded values
- 6384
- 204193
- Applicant
- HIKMA
- Approval date
- 30 Sept 1982
- Application number
- NDA018123
- First in class
- No
- Orphan designation
- No
- Availability
- discontinued
- Pharmacology name
- [125I]GnRH I (human, mouse, rat)
- Type
- Peptide
- Drug name stem
- -relin
Administration routes
- Parenteral
Mechanisms of action
- Action
- Full agonist
- Action type
- FULL_AGONIST
- Target
- GnRH1 receptor
- Gene symbol
- GNRHR
- Protein identifier
- P30968
Open Targets mechanisms
- Mechanism
- Gonadotropin-releasing hormone receptor agonist
- Action type
- Agonist
- Target
- Gonadotropin-releasing hormone receptor
DrugCentral mechanisms
- Action type
- Agonist
- Gene symbol
- GNRHR
- Protein identifier
- P30968
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Cocaine-Related Disorders
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002610
- Subject identifier
- D019970
- Condition
- Osteoporosis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003882
- Subject identifier
- D010024
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Prostatic Neoplasms, Castration-Resistant
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0008315
- Subject identifier
- D064129
- Condition identifier
- EFO_0000195
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000545
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002950
- Highest recorded phase
- 3
- Condition identifier
- EFO_0008008
- Condition identifier
- EFO_1000653
- Condition identifier
- GO_0042697
- Highest recorded phase
- 2
- Condition identifier
- HP_0000131
- Condition identifier
- HP_0000786
- Highest recorded phase
- 2
- Condition identifier
- HP_0000789
- Highest recorded phase
- 3
- Condition identifier
- HP_0000822
- Highest recorded phase
- 1
- Condition identifier
- HP_0000823
- Highest recorded phase
- 1
- Condition identifier
- HP_0001513
- Condition identifier
- HP_0001518
- Condition identifier
- HP_0008209
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0000521
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000596
- Condition identifier
- MONDO_0001119
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0001572
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002146
- Condition identifier
- MONDO_0002447
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004975
- Condition identifier
- MONDO_0004995
- Condition identifier
- MONDO_0005044
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005047
- Highest recorded phase
- 3
And 17 more, listed on the interactive page.
- Event
- activated pi3 kinase delta syndrome
- Reports
- 1
- Reporting signal score
- 9.01185
- Event
- breast cancer
- Reports
- 7
- Reporting signal score
- 25.5881
- Event
- carcinoembryonic antigen increased
- Reports
- 3
- Reporting signal score
- 16.9686
- Event
- central nervous system lesion
- Reports
- 5
- Reporting signal score
- 22.0346
- Event
- malignant neoplasm progression
- Reports
- 6
- Reporting signal score
- 17.0197
- Event
- meningeal disorder
- Reports
- 4
- Reporting signal score
- 28.8867
- Event
- metastases to bone
- Reports
- 6
- Reporting signal score
- 26.3439
- Event
- neutropenia
- Reports
- 6
- Reporting signal score
- 11.6784
- Event
- ovarian disorder
- Reports
- 2
- Reporting signal score
- 12.0723
- Event
- ovarian hyperstimulation syndrome
- Reports
- 4
- Reporting signal score
- 20.8793
- Event
- pigmentary glaucoma
- Reports
- 1
- Reporting signal score
- 8.65519
- Event
- reproductive tract hypoplasia, male
- Reports
- 1
- Reporting signal score
- 8.47288
- Event
- uterine disorder
- Reports
- 2
- Reporting signal score
- 10.0115
- Event
- uterine enlargement
- Reports
- 2
- Reporting signal score
- 12.8088
- Event
- visual impairment
- Reports
- 4
- Reporting signal score
- 9.67962
- NCT00000325
- NCT00175383
- NCT00329797
- NCT01603420
- NCT03009981
- NCT04293393
- Dose
- 100 mcg
- Route
- Intramuscular
- How often
- As specified in program steps
- Calculated partition coefficient (XLogP)
- -2.4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 85
- Molecular formula
- C55H75N17O13
- Monoisotopic mass
- 1181.57302551
- Natural product
- Yes
Sequences
- Component
- Sequence
- Type
- Protein
- Sequence
- QHWSYGLRPG
- Recorded assays
- 34
- Active assays
- 6
- Confirmatory
- Other
These details could not be displayed.
Related records
Trials (285)
- 12-week Open-label Evaluation of Efficacy and Safety of Indacaterol
- 90% Effective Dose of Norepinephrine Infusions Under Intensive and Standard Treatment
- 90% Effective Dose of Norepinephrine Infusions Under Intensive and Standard Treatment in Preeclamptic Patients
- 90% Effective Dose of Phenylephrine Infusions Under Intensive and Standard Treatment
- 90% Effective Dose of Phenylephrine Infusions Under Intensive and Standard Treatment in Preeclamptic Patients
- A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
- A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH
- A Novel Drug for Borderline Personality Disorder
- A Novel Stimulation Protocol and the Conventional Low Dose Step-up and Step Down Regimens
- A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
- A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer
- A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
- A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
- A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
- A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
- A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.
In development for (5)
- Breast cancer Phase 2
- Cocaine dependence Phase 1
- Infertility disorder Phase 3
- Osteoporosis Phase 3
- Prostate cancer Phase 3
Other linked conditions (1)
- Hypogonadotropic hypogonadism
Targets (1)
- GNRHR Gonadotropin-releasing hormone receptor agonist